NCT06649474View on ClinicalTrials.gov

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

NARecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions

Pancreatic CancerResectable Pancreatic AdenocarcinomaAdenocarcinomaResectable Esophageal CancerResectable Gastric or Gastroesophageal Junction AdenocarcinomaOesophagogastric Cancer

Interventions

BIOLOGICAL

assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy

assess the serum HMGB1 concentrations

Trial Locations (1)

63000

RECRUITING

CHU Estaing de Clermont-Ferrand, Clermont-Ferrand

All Listed Sponsors

lead

University Hospital, Clermont-Ferrand

OTHER